Axitinib, cabozantinib, and lenvatinib are first-line treatment options.
Dane Fritzsche, PharmD, BCOP
Advertisement
Articles by Dane Fritzsche, PharmD, BCOP
New agents can offer a more tailored approach to therapy selection.
Melanoma is responsible for 80% of skin cancer deaths.
Advertisement
Latest Updated Articles
Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant SettingPublished: October 11th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
FDA Approves First Drug for Pediatrics With Irritable Bowel Syndrome With Constipation
3
Regular Melatonin Supplementation May Hide Hidden Heart Complications
4
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
5
